T-Cell Metabolism in Graft Versus Host Disease

Karl F, Hudecek M, Berberich-Siebelt F, Mackensen A, Mougiakakos D (2021)


Publication Type: Journal article, Review article

Publication year: 2021

Journal

Book Volume: 12

DOI: 10.3389/fimmu.2021.760008

Abstract

Allogeneic-hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment option for numerous hematological malignancies. Elimination of malignant cells depends on the T-cells' Graft-versus-Tumor (GvT) effect. However, Graft-versus-Host-Disease (GvHD), often co-occurring with GvT, remains an obstacle for therapeutic efficacy. Hence, approaches, which selectively alleviate GvHD without compromising GvT activity, are needed. As already explored for autoimmune and inflammatory disorders, immuno-metabolic interventions pose a promising option to address this unmet challenge. Being embedded in a complex regulatory framework, immunological and metabolic pathways are closely intertwined, which is demonstrated by metabolic reprograming of T-cells upon activation or differentiation. In this review, current knowledge on the immuno-metabolic signature of GvHD-driving T-cells is summarized and approaches to metabolically interfere are outlined. Furthermore, we address the metabolic impact of standard medications for GvHD treatment and prophylaxis, which, in conjunction with the immuno-metabolic profile of alloreactive T-cells, could allow more targeted interventions in the future.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Karl, F., Hudecek, M., Berberich-Siebelt, F., Mackensen, A., & Mougiakakos, D. (2021). T-Cell Metabolism in Graft Versus Host Disease. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.760008

MLA:

Karl, Franziska, et al. "T-Cell Metabolism in Graft Versus Host Disease." Frontiers in Immunology 12 (2021).

BibTeX: Download